Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
CompletedNCT04768335
Official study titlePilot Study: the Links Between Basic Auditory Processes and High Functioning Cognitive Processes in Schizophrenia (Reality Monitoring and Emotional Perception)
This study has finished and is no longer accepting participants.
In BronSchizophreniaBehavioural studyAges 18–65
- Countries
- France
- Sponsor
- Hôpital le Vinatier
CompletedNCT01886417
Official study titleElectromyography Study of Lip Muscles During Auditory Verbal Hallucinations Without Subvocalization in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In GrenobleSchizophreniaObservational studyAges 18–60
- Countries
- France
- Sponsor
- University Hospital, Grenoble
CompletedNCT03585127
Official study titleA Pilot Randomized Controlled Study to Compare Avatar Therapy and Cognitive Behavioral Therapy in Patients With Treatment-resistant Schizophrenia.
This study has finished and is no longer accepting participants.
In MontrealSchizophreniaBehavioural studyAges 18+
- Countries
- Canada
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
CompletedNCT02716584
Official study titlePhysical Exercise Effects on Determinants of Social Integration in Schizophrenia
This study has finished and is no longer accepting participants.
In West Los AngelesSchizophreniaBehavioural studyAges 40–65
- Countries
- United States
- Sponsor
- VA Office of Research and Development (Government agency)
CompletedNCT02936414
This study has finished and is no longer accepting participants.
In TianjinSchizophreniaMedication studyAges 18–60
- Countries
- China
- Sponsor
- Tianjin Anding Hospital
CompletedNCT03251716
Official study titleBerberine in the Treatment of Metabolic Syndrome : an Open Label Clinical Study in Female Schizophrenia Patients
This study has finished and is no longer accepting participants.
In TianjinSchizophreniaMedication studyAges 18–60
- Countries
- China
- Sponsor
- Tianjin Anding Hospital
TerminatedNCT00712270
Official study titleA Randomized Double-blind Trial of Aripiprazole and Risperidone in Schizophrenia: An Evaluation of Neuroimaging, Neuropsychological, and Pharmacogenomic Markers of Differential Treatment Response
This study ended early.
In KetteringSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Kettering Health Network
CompletedNCT00535574
Official study titleBexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia: a 6-week, Randomized, Double-blind Placebo-controlled Trial
This study has finished and is no longer accepting participants.
Multiple locations, including BeershebaSchizophreniaMedication studyAges 18–60
- Countries
- Israel
- Sponsor
- Beersheva Mental Health Center
TerminatedNCT00861497
What is this study about?Researchers are studying Bifeprunox, tracking side effects to assess safety in people with schizophrenia.
This study ended early.
In BresciaSchizophreniaMedication studyAges 18+
- Countries
- Italy
- Sponsor
- H. Lundbeck A/S
CompletedNCT00193713
Official study titleA Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–75
- Countries
- Sponsor
- Solvay Pharmaceuticals
CompletedNCT00540267
Official study titleBone Mineral Density in the Korean Patients With Chronic Schizophrenia With Alcohol Abuse
This study has finished and is no longer accepting participants.
In BusanSchizophreniaObservational studyAges 18–80
- Countries
- South Korea
- Sponsor
- Inje University
CompletedNCT00431223
Official study titleDoes Computerized Cognitive Skills Training Change Brain Activation Patterns in Schizophrenia?
This study has finished and is no longer accepting participants.
In New YorkSchizophreniaBehavioural studyAges 18–55
- Countries
- United States
- Sponsor
- Manhattan Psychiatric Center